TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Tenax Therapeutics, Inc.

ONE Copley Parkway
Suite 490
Morrisville, NC 27560
United States
919-855-2100
http://www.tenaxthera.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael B. JebsenInterim CEO, Pres & CFO471.25kN/A1971
Mr. John P. KelleyConsultant720.25kN/A1954
Ms. Nancy J. M. HecoxExec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.N/AN/AN/A
Maria Isabel TomargoAssistant VP of Marketing & SalesN/AN/AN/A
Mr. Robert F. Diegelmann Ph.D.Head of New Wound Care DivisionN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Corporate Governance

Tenax Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.